TriNetX and Fujitsu Launch Joint Venture to Increase Japanese Patients' Access to Life-Changing Medicines
TriNetX and Fujitsu have formed a joint venture, TriNetX Japan K.K., to enhance clinical trials and drug development in Japan. The partnership combines TriNetX's global network of over 200 million patient records with Fujitsu's cloud-based healthcare platform in Japan. The venture aims to utilize anonymized electronic health record (EHR) data from Japanese patients while complying with strict data privacy regulations.
The initiative targets Japan's pharmaceutical market, the world's third-largest, with particular focus on studying age-related conditions given Japan's aging population. The joint venture will integrate the TriNetX LIVE™ Platform with Fujitsu's healthcare sector platform, providing researchers and pharmaceutical companies secure access to large-scale EHR datasets.
The collaboration builds upon TriNetX's 2022 entry into the Japanese market and aligns with the increasing number of Japanese medical institutions joining the TriNetX network. Shogo Wakabayashi will lead the new entity as Country Manager.
TriNetX e Fujitsu hanno formato una joint venture, TriNetX Japan K.K., per migliorare le sperimentazioni cliniche e lo sviluppo di farmaci in Giappone. La partnership combina la rete globale di TriNetX, che conta oltre 200 milioni di cartelle cliniche, con la piattaforma sanitaria basata su cloud di Fujitsu in Giappone. L'iniziativa mira a utilizzare dati anonimizzati delle cartelle cliniche elettroniche (EHR) dei pazienti giapponesi, rispettando le rigorose normative sulla privacy dei dati.
Il progetto si rivolge al mercato farmaceutico giapponese, il terzo più grande al mondo, con particolare attenzione allo studio delle condizioni legate all'età, data la popolazione in invecchiamento del Giappone. La joint venture integrerà la TriNetX LIVE™ Platform con la piattaforma del settore sanitario di Fujitsu, fornendo ai ricercatori e alle aziende farmaceutiche un accesso sicuro a set di dati EHR su larga scala.
La collaborazione si basa sull'ingresso di TriNetX nel mercato giapponese nel 2022 e si allinea con il numero crescente di istituzioni mediche giapponesi che si uniscono alla rete TriNetX. Shogo Wakabayashi guiderà la nuova entità come Country Manager.
TriNetX y Fujitsu han formado una empresa conjunta, TriNetX Japan K.K., para mejorar los ensayos clínicos y el desarrollo de medicamentos en Japón. La asociación combina la red global de TriNetX, que cuenta con más de 200 millones de registros de pacientes, con la plataforma de salud en la nube de Fujitsu en Japón. La iniciativa tiene como objetivo utilizar datos de registros de salud electrónicos (EHR) anonimizados de pacientes japoneses, cumpliendo con estrictas regulaciones de privacidad de datos.
La iniciativa se dirige al mercado farmacéutico de Japón, el tercero más grande del mundo, con un enfoque particular en el estudio de condiciones relacionadas con la edad, dada la población envejecida de Japón. La empresa conjunta integrará la TriNetX LIVE™ Platform con la plataforma del sector salud de Fujitsu, proporcionando a investigadores y empresas farmacéuticas un acceso seguro a grandes conjuntos de datos de EHR.
La colaboración se basa en la entrada de TriNetX en el mercado japonés en 2022 y se alinea con el creciente número de instituciones médicas japonesas que se unen a la red TriNetX. Shogo Wakabayashi liderará la nueva entidad como Country Manager.
TriNetX와 후지쯔는 일본에서 임상 시험 및 의약품 개발을 강화하기 위해 합작회사인 TriNetX Japan K.K.를 설립했습니다. 이 파트너십은 TriNetX의 2억 개 이상의 환자 기록을 포함하는 글로벌 네트워크와 일본에서 후지쯔의 클라우드 기반 헬스케어 플랫폼을 결합합니다. 이 사업은 일본 환자의 익명화된 전자 건강 기록(EHR) 데이터를 이용하면서도 엄격한 데이터 개인정보 보호 규정을 준수하는 것을 목표로 합니다.
이 이니셔티브는 세계에서 세 번째로 큰 일본의 제약 시장을 겨냥하고 있으며, 일본의 고령화 인구를 고려하여 노화 관련 질환 연구에 특히 중점을 두고 있습니다. 합작회사는 TriNetX LIVE™ Platform을 후지쯔의 헬스케어 부문 플랫폼과 통합하여 연구자와 제약 회사가 대규모 EHR 데이터 세트에 안전하게 접근할 수 있도록 합니다.
이번 협력은 2022년 TriNetX의 일본 시장 진출을 기반으로 하며, TriNetX 네트워크에 합류하는 일본 의료 기관의 수가 증가하는 추세와 일치합니다. 새로운 법인은 Shogo Wakabayashi가 Country Manager로 이끌게 됩니다.
TriNetX et Fujitsu ont formé une coentreprise, TriNetX Japan K.K., pour améliorer les essais cliniques et le développement de médicaments au Japon. Le partenariat combine le réseau mondial de TriNetX, qui compte plus de 200 millions de dossiers patients, avec la plateforme de santé basée sur le cloud de Fujitsu au Japon. L'initiative vise à utiliser des données de dossiers de santé électroniques (EHR) anonymisées provenant de patients japonais tout en respectant des réglementations strictes en matière de confidentialité des données.
Cette initiative cible le marché pharmaceutique japonais, le troisième plus grand au monde, en mettant particulièrement l'accent sur l'étude des conditions liées à l'âge, compte tenu du vieillissement de la population japonaise. La coentreprise intégrera la TriNetX LIVE™ Platform avec la plateforme du secteur de la santé de Fujitsu, offrant aux chercheurs et aux entreprises pharmaceutiques un accès sécurisé à de grands ensembles de données EHR.
Cette collaboration repose sur l'entrée de TriNetX sur le marché japonais en 2022 et s'aligne avec le nombre croissant d'institutions médicales japonaises rejoignant le réseau TriNetX. Shogo Wakabayashi dirigera la nouvelle entité en tant que Country Manager.
TriNetX und Fujitsu haben ein Joint Venture, TriNetX Japan K.K., gegründet, um klinische Studien und die Medikamentenentwicklung in Japan zu verbessern. Die Partnerschaft kombiniert das globale Netzwerk von TriNetX mit über 200 Millionen Patientenakten mit Fujitsus cloudbasierter Gesundheitsplattform in Japan. Das Vorhaben zielt darauf ab, anonymisierte elektronische Gesundheitsdaten (EHR) von japanischen Patienten zu nutzen und dabei strenge Datenschutzvorschriften einzuhalten.
Die Initiative richtet sich an den japanischen Pharmamarkt, den drittgrößten der Welt, mit besonderem Fokus auf die Erforschung altersbedingter Erkrankungen, angesichts der alternden Bevölkerung Japans. Das Joint Venture wird die TriNetX LIVE™ Platform mit Fujitsus Gesundheitsplattform integrieren und Forschern sowie Pharmaunternehmen sicheren Zugang zu umfangreichen EHR-Datensätzen bieten.
Die Zusammenarbeit baut auf dem Markteintritt von TriNetX in Japan im Jahr 2022 auf und steht im Einklang mit der steigenden Zahl japanischer medizinischer Einrichtungen, die sich dem TriNetX-Netzwerk anschließen. Shogo Wakabayashi wird die neue Einheit als Country Manager leiten.
- Access to Japan's third-largest pharmaceutical market
- Integration of TriNetX's 200M+ patient records with Fujitsu's healthcare platform
- Expansion of research capabilities in the growing Japanese market
- Strategic positioning in Japan's aging population healthcare sector
- None.
Partnership taps real-world data to accelerate clinical trials, research, and drug development in
The initiative represents a significant step forward for integrating
"Since our full-scale entry into the Japanese market in 2022, TriNetX has been enabling pharmaceutical companies and researchers to securely leverage anonymous patient data through our federated system while ensuring compliance with
The new entity will integrate the TriNetX LIVE™ Platform, TriNetX's global network of over 200 million patient records, with Fujitsu's cloud-based platform for the healthcare sector in
Tatsuki Araki, Head of Healthy Living of Fujitsu, remarked, "Fujitsu is proud to collaborate with TriNetX to advance healthcare and life sciences innovation in
The TriNetX-Fujitsu joint venture aligns with the growing number of Japanese medical institutions joining the TriNetX network. Researchers are already conducting novel studies using TriNetX data and technology, while pharmaceutical companies are increasingly offering clinical trial opportunities to these institutions.
Shogo Wakabayashi, TriNetX's Country Manager,
About TriNetX, LLC
TriNetX is a global network of healthcare organizations and life sciences companies dedicated to advancing real-world research and expediting the development of new therapies. Through its self-service, HIPAA-, GDPR-, and LGPD-compliant platform of federated deidentified and anonymous electronic health record datasets and consulting partnerships, TriNetX empowers its global community to improve clinical trial protocol design, streamline trial operations, refine safety signals, and enrich real-world evidence generation. For more information, please visit TriNetX at www.trinetx.com or follow TriNetX on LinkedIn.
About Fujitsu
Fujitsu's purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers in over 100 countries, our 124,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: Computing, Networks, AI, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of
Media Contact
TriNetX
Karen Tunks
Email: Karen.Tunks@TriNetX.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/trinetx-and-fujitsu-launch-joint-venture-to-increase-japanese-patients-access-to-life-changing-medicines-302374050.html
SOURCE TriNetX
FAQ
What is the purpose of the TriNetX-Fujitsu (FJTSY) joint venture in Japan?
How many patient records will be accessible through the TriNetX-FJTSY partnership?
When did TriNetX enter the Japanese market before partnering with FJTSY?
Who will lead the TriNetX Japan K.K. joint venture with FJTSY?
What technology platforms will be integrated in the TriNetX-FJTSY partnership?
